News
B. Riley Securities Maintains Buy on Viridian Therapeutics, Lowers Price Target to $25
21 Mar 24
News, Price Target, Analyst Ratings
Unveiling 4 Analyst Insights On Viridian Therapeutics
20 Mar 24
Analyst Ratings
Needham Maintains Buy on Viridian Therapeutics, Maintains $30 Price Target
20 Mar 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $37 Price Target
29 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Navigating 6 Analyst Ratings For Viridian Therapeutics
28 Feb 24
Analyst Ratings
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $40
28 Feb 24
News, Price Target, Analyst Ratings
Needham Reiterates Buy on Viridian Therapeutics, Maintains $30 Price Target
28 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Viridian Therapeutics Q4 2023 GAAP EPS $(1.35) Misses $(0.97) Estimate, Sales $72.00K Miss $159.60K Estimate
27 Feb 24
Earnings, Earnings Misses, News
Press releases
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Apr 24
Press Releases
VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
29 Mar 24
Press Releases
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 Mar 24
Press Releases
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
Press Releases
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
16 Feb 24
Press Releases
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
6 Feb 24
Press Releases